SEC Watch is The Investigative Journal’s daily review of notable filings on the Securities and Exchange Commission’s EDGAR system, together with the Commission’s enforcement docket. Every item below is drawn directly from public records, each linked at the point of reference.
Monday’s filing day produced an unusually dense slate of disclosure events. An August 17 litigation release announced fraud charges over an alleged $74 million “pre-IPO” boiler-room operation; a Nasdaq-listed aquaculture company told investors to stop relying on two years of its financial statements; ResMed dismissed KPMG after a competitive audit review; and FedEx and Medtronic both filed definitive proxy statements ahead of fall annual meetings. Here is what stands out, and why it matters.
1. SEC alleges $74 million pre-IPO “boiler room” run through more than 100 sales agents
In the most significant enforcement action of the new week, the SEC charged New York resident Andrew Spaventa and three entities he owned and controlled — The Spaventa Group LLC, TSG Capital Advisors LLC, and TSG Alpha Partners LLC — with defrauding retail investors through unregistered offerings of eleven private funds that purported to give ordinary investors access to shares of “pre-IPO” private companies. The complaint was filed August 14 in the Southern District of New York, and the Commission announced it in Litigation Release No. 26611, dated August 17.
According to the SEC’s complaint, between roughly December 2020 and June 2025 the defendants raised more than $74 million from over 800 mostly retail investors. The filings allege a two-layer structure: Spaventa’s entities bought pre-IPO shares, then resold them to his own funds in principal transactions at marked-up prices — with investors paying, on average, approximately 46 percent more than Spaventa paid, despite being told upfront fees would be zero or capped at 12.5 percent. The complaint further alleges that more than 100 “sales agents” cold-called thousands of prospective investors, many of them retirees, using high-pressure tactics, and that roughly $23 million in fees was extracted — over $12 million of it paid out as sales commissions and about $4 million to Spaventa personally.
The charges span the antifraud, securities registration, and broker-dealer registration provisions of the Securities Act, the Exchange Act, and the Investment Advisers Act. These are allegations in a pending civil action; no findings have been made, and the defendants have not yet responded in court. The case lands amid a visible Commission focus on the private-market access pitch — a theme that also runs through the Adit Ventures matter below.
2. Nocera tells investors: don’t rely on fiscal 2024 and 2025 financial statements
Nocera, Inc. (Nasdaq: NCRA), a Nevada-incorporated, Taiwan-headquartered aquaculture company, filed an 8-K under Item 4.02 — non-reliance on previously issued financial statements — disclosing that on August 14 its board concluded that audited financials for fiscal years 2024 and 2025, plus unaudited interim statements for the first three quarters of 2025, “should no longer be relied upon due to errors.”
The restatement detail in the filing is substantial. The company records a reduction of goodwill of approximately $1.35 million, cutting the carrying amount for fiscal 2024 from $2,077,728 to $726,025. The filing also discloses write-offs or reclassifications of certain receivables, prepaid expenses, and fixed assets, roughly $110,669 in additional income tax payable, and unrecognized lease assets and liabilities. The aggregate effect, per the filing, is an increase in accumulated losses of approximately $2.1 million as of December 31, 2024, and a reduction of previously reported fiscal 2025 net sales of approximately $2.6 million — though reported net losses for both years are stated to be unchanged. The company attributes the errors to previously disclosed material weaknesses in internal control over financial reporting, including inadequate documentation, monitoring, and segregation of duties.
Context matters here: the SEC announced on August 5 that it is standing up a dedicated Financial Reporting and Accounting Unit within the Division of Enforcement to pursue accounting and reporting fraud. Small-cap restatements paired with acknowledged control weaknesses are precisely the fact pattern such a unit screens. Records show the audit work is performed by SFAI Malaysia PLT; the restated figures appear in a second amendment to the company’s 10-K filed concurrently.
3. ResMed dismisses KPMG, hires PwC — and a board transition follows
ResMed Inc. (NYSE: RMD), the San Diego-based sleep-device maker, disclosed in an 8-K filed Monday that its audit committee dismissed KPMG LLP effective August 13 and appointed PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending June 30, 2027, following what the filing describes as a competitive review process. Importantly for investors, the filing states there were no disagreements or reportable events with KPMG during the last two fiscal years, and KPMG’s letter to the Commission is attached as Exhibit 16.1. An auditor change at a large-cap issuer with a clean Item 4.01 is not itself a red flag, but it is a data point worth tracking through the first PwC-audited cycle.
The same filing discloses that director Ronald Taylor will retire at the annual meeting expected on November 18, 2026 — expressly not due to any disagreement, per the filing — and that Carol Burt will become lead director effective November 15. The company’s press release is furnished as Exhibit 99.1.
4. Limoneira sells Paso Robles vineyards at auction; aggregate impairment reaches $13.4 million
Agribusiness Limoneira Company (Nasdaq: LMNR) filed an 8-K disclosing that a subsidiary agreed on August 15 to sell five Paso Robles, California vineyard properties — roughly 724 acres — for $15 million to buyer Paul Rusnak, following a public auction conducted by Concierge Auctions. The deal, per the filing, is not conditioned on financing or further diligence, carries a 12 percent earnest deposit, and is scheduled to close no later than September 14, 2026. The buyer excluded the 2026 harvest, leaving Limoneira the current crop and farming access through November 30.
The disclosure that warrants attention sits in Item 2.06: the company expects an additional impairment charge of approximately $4.1 million in its fiscal fourth quarter as a result of this sale — on top of the approximately $9.3 million impairment recognized after an earlier sale of the same properties was terminated in April — for an aggregate impairment of approximately $13.4 million against a $15 million sale price. Filings indicate a difficult monetization path for these non-core assets; the company frames the sale as consistent with its strategy to enhance liquidity. The company’s press release accompanies the filing.
5. Proxy season, fall edition: FedEx and Medtronic file definitive proxy statements
Two mega-caps filed DEF 14A proxy statements Monday. FedEx Corporation’s definitive proxy sets up its annual meeting for September 28, 2026, and — as with every proxy — carries the year’s authoritative disclosures on director nominees, executive compensation, and shareholder proposals. Medtronic plc’s definitive proxy points to an October 15, 2026 annual meeting. TIJ will review both documents’ compensation tables, pay-versus-performance disclosures, and any shareholder proposals in a follow-up; readers can inspect the primary documents at the links above.
6. $47 million affinity fraud charges out of Toms River
On August 13, the SEC charged three Toms River, New Jersey residents in an alleged affinity fraud that raised approximately $47 million from more than 87 investors, primarily members of Orthodox Jewish communities in New Jersey and New York. The complaint, filed in the District of New Jersey, alleges that Leor Moshe told investors his company, Capital Funding ASAP LLC, would fund short-term small-business loans with fixed returns — in some cases promised at more than thirty percent — while in fact misappropriating more than $11 million for personal use and making over $850,000 in Ponzi-like payments to earlier investors. An SEC associate director summarized the pitch as one that “falls into the ‘if it sounds too good to be true, it probably is’ category.”
Two other residents, Jacob Goldman and Isaac Odes, are charged with acting as unregistered brokers, allegedly soliciting more than $23 million from at least 25 investors. According to the complaint, investor losses exceed $25 million across seven states. The U.S. Attorney’s Office for the District of New Jersey announced parallel criminal charges against Moshe. All of these are allegations; the civil and criminal cases are pending, and no defendant has been adjudicated liable.
7. Pre-IPO theme, part two: Adit Ventures settles fraud charges over SpaceX and Klarna funds
Rounding out the enforcement docket, the SEC on August 10 charged New York adviser Adit Ventures Management LLC, CEO Eric Munson, and three affiliated general partners with defrauding investors in funds built around pre-IPO shares of companies such as SpaceX and Klarna. The complaint alleges undisclosed markups on principal transactions, millions in unauthorized “acquisition fees,” unsecured insider loans on favorable terms, and client assets pledged as collateral for a $10 million credit line used partly to pay the defendants’ own obligations.
Without admitting the allegations, the defendants consented to a judgment — subject to court approval — including permanent injunctions and monetary relief to be set by the court, with Munson agreeing to an associational bar with a right to reapply after three years. Taken together with the Spaventa case above, the records suggest the Commission’s Asset Management Unit is working systematically through the retail pre-IPO fund niche — a corner of the market where valuation opacity makes hidden-fee allegations hard for investors to detect.
On TIJ’s radar: filings that warrant a closer look
Several smaller items from Monday’s tape merit follow-up reporting. Baltic International USA Inc. filed three separate 10-Q reports within minutes of one another on Monday afternoon — a pattern that typically indicates a delinquent filer catching up on multiple past quarters, and worth understanding before any investor relies on the freshly filed numbers. Helix Acquisition Corp. III filed an 8-K under Item 3.01, the item reserved for delisting notices or failures to satisfy a continued listing standard. Coherus Oncology filed twin 8-Ks Monday evening covering a material agreement, a termination, and the creation of a direct financial obligation — a cluster that suggests a refinancing worth parsing. And with the August 14 deadline for second-quarter Form 13F institutional holdings reports now past, this week’s 13F tape consists largely of stragglers and amendments; TIJ will return to the quarter’s notable position changes once the full dataset settles.
Editor’s note: This digest is compiled exclusively from public records — SEC EDGAR filings, litigation releases, and Commission press releases — each linked above. Enforcement matters described here are allegations unless otherwise stated, and pending cases have not been adjudicated. Companies and individuals named in this report who wish to respond may contact the editorial desk; responses will be noted in updates to this article. Nothing here is investment advice.
Photo credit: U.S. Securities and Exchange Commission headquarters, Washington, D.C. Photograph by AgnosticPreachersKid, via Wikimedia Commons, licensed under CC BY-SA 3.0.
